External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>Adicet Bio is a biotech company working on developing an off-the-shelf CD20 gamma delta CAR-T cell therapy for autoimmune diseases, particularly lupus nephritis</li><li>The company also has gamma delta CAR-T programs targeting various cancers, with value inflection data points expected in 2024 and 2025</li><li>Despite trading at a negative enterprise value, Adicet has significant cash reserves and a manageable quarterly spend, making its equity potentially underpriced compared to peers, with the potential success of its autoimmune program leading to a stock re-rating.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Adicet Bio is a biotech company working on developing an off-the-shelf CD20 gamma delta CAR-T cell therapy for autoimmune diseases, particularly lupus nephritisThe company also has gamma delta CAR-T programs targeting various cancers, with value inflection data points expected in 2024 and 2025Despite trading at a negative enterprise value, Adicet has significant cash reserves and a manageable quarterly spend, making its equity potentially underpriced compared to peers, with the potential success of its autoimmune program leading to a stock re-rating.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Adicet Bio Inc (ACET) - Thursday, Jul 18, 2024

United States

Adicet Bio, Inc. operates as a clinical-stage bio-pharmaceutical company. The Company designs and develops of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Adicet Bio (ACET US)

Adicet Bio Inc (ACET) - Thursday, Jul 18, 2024

Adicet Bio is a biotech company working on developing an off-the-shelf CD20 gamma delta CAR-T cell therapy for autoimmune diseases, particularly...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)